This website is owned and developed by Boehringer Ingelheim and contains promotional information.
This website is intended for UK Healthcare Professionals only. If you are not a Healthcare Professional in the UK please click here.
Click here for OFEV® (nintedanib) UK prescribing information. Find adverse event reporting information at the bottom of this page.

Resources

England ILD Specialist Centres Interactive Map

There are specialist interstitial lung disease (ILD) centres across England which have the
ability to prescribe antifibrotic therapies for patients with idiopathic pulmonary fibrosis (IPF).

This interactive tool has been designed to help you locate your two nearest ILD Specialist Centres.

This interactive tool is designed to assist HCPs in England who are looking to refer their IPF patients to an ILD specialist centre who is able to prescribe antifibrotic therapies.

If you are a healthcare professional in Wales, Scotland, or Northern Ireland please refer all of your IPF patients to your local respiratory service.


References

  1. OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) or by email to PV_local_uk_ireland@boehringer-ingelheim.com.


OFEV® (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. The recommended dose is one 150 mg capsule taken twice daily.1